42 results
8-K
EX-1.1
TRML
Tourmaline Bio Inc
26 Jan 24
Other Events
4:12pm
and in connection with the transactions contemplated hereby, including without limitation: (i) all expenses incident to the issuance and delivery
8-K
EX-99.2
TRML
Tourmaline Bio Inc
24 Jan 24
Results of Operations and Financial Condition
5:10pm
to increase in connection with our ongoing activities as described in greater detail below. We are subject to all the risks incident in the development
8-K
EX-99.1
TRML
Tourmaline Bio Inc
24 Jan 24
Results of Operations and Financial Condition
5:10pm
estimate that 15,000 to 20,000 patients out of the incident population in the United States have moderate to severe, active, inflammatory TED that may
424B3
j5lz233
15 Sep 23
Prospectus supplement
6:31am
S-4/A
a6feplhex c8c
25 Aug 23
Registration of securities issued in business combination transactions (amended)
4:34pm
S-4
EX-3.3
la4ktph96i00eciy94v
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
S-4
xjl44j 0z6u
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
S-4
EX-10.6
bfvfpn6apkz4bsqeyk3
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
425
l85sy
22 Jun 23
Business combination disclosure
9:12am
8-K
EX-2.1
efo7q5qwo ijw2
22 Jun 23
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
9:10am
S-3
EX-1.2
qb80yvfxqwt xoeebi
15 Aug 22
Shelf registration
5:06pm